TICKERNERD
Menu
AVTXAVTXHealthcare · Biotechnology

AVTX Stock Forecast: Avalo Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$7.17
−3.63% on the day

The 14 Wall Street analysts covering Avalo Therapeutics, Inc. hold a median 12-month price target of $39 — +437.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 31 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$384.5M
Ticker Nerd rank
27/ 100
Median analyst target
$39
Analysts covering
14
Revenue$0.0
Operating income−$31.5M
Net income−$36.4M
Free cash flow−$20.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.5%
1M
−53.2%
YTD
−60.5%
1Y
−60.2%
From 52W high
−68.6%
From 52W low
+6.2%
$7
$23
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AVTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Avalo Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
27/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
65
Size
56
Revisions
46
Accruals
46
Growth
45
Momentum
41
Volatility
28
Issuance
25
Value
14

Quality (65): The business earns solid, repeatable profits on what it owns.

Value (14): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

AVTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AVTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26AVTXHigh $60Median $39Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
12 Buy2 Hold0 Sell
Low $10Median $39High $60

The green dot is the last close — the median target sits +437.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
23 Oct 2026BTIGMaintainsBuy$58 → $10
23 Oct 2026GuggenheimDowngradeNeutral—
23 Oct 2026HC Wainwright & Co.DowngradeNeutral—
23 Oct 2026WedbushMaintainsOutperform$34 → $22
7 Aug 2026GuggenheimMaintainsBuy—
7 Aug 2026GuggenheimMaintainsBuy$50 → $48
7 Aug 2026HC Wainwright & Co.MaintainsBuy$35 → $30
7 Aug 2026HC Wainwright & Co.MaintainsBuy—
6 July 2026Leerink PartnersInitiatesOutperform$38
6 July 2026Leerink PartnersInitiatesOutperform—
16 June 2026BTIGReiteratesBuy—
12 June 2026B of A SecuritiesInitiatesBuy—
14 May 2026CitizensMaintainsMarket Outperform—
14 May 2026HC Wainwright & Co.MaintainsBuy—
14 May 2026MizuhoMaintainsOutperform—
14 May 2026WedbushMaintainsOutperform—
11 May 2026Piper SandlerMaintainsOverweight—
6 May 2026BTIGMaintainsBuy—
6 May 2026CitizensMaintainsMarket Outperform—
6 May 2026WedbushMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

AVTX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

AVTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Avalo Therapeutics, Inc. returned −60.2% against +12.4% for the S&P 500, dividends included.

AVTX vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26AVTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AVTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
3
Analysts cutting
4
Fundamentals

Avalo Therapeutics, Inc. (AVTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.3×

Cheaper than 69% of US stocks

Price / sales
6426.5×

Cheaper than 1% of US stocks

Price / book
0.8×

Cheaper than 75% of US stocks

EV / EBITDA
0.0×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−154847.5%

Higher than 1% of US stocks

Net margin
100.0%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−36.3%

Higher than 25% of US stocks

Return on assets
−18.5%

Higher than 20% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Avalo Therapeutics, Inc. (AVTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Avalo Therapeutics, Inc. has a market value of $384.5M and an enterprise value of −$1.0M.

  • Revenue in the twelve months to 30 June 2026: $59K. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$100.3M, a −170055.9% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$68.3M.

  • Shares outstanding: 52.9M.

  • Trailing P/E: 2.3×; forward P/E: −2.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Avalo Therapeutics, Inc. employs 33 people — $2K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 30 Oct 2026

Data provided by Twelve Data

Peers

AVTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AVTXAvalo Therapeutics, Inc.$384.5M27
RZLTRezolute, Inc.$378.0M37
RLMDRelmada Therapeutics, Inc.$375.5M62
ZURAZura Bio Ltd.$383.3M31
TECXTectonic Therapeutic, Inc.$370.2M51
CAPRCapricor Therapeutics, Inc.$366.9M16
CTNMContineum Therapeutics, Inc.$363.9M38

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Avalo Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AVTX news & analysis

Avalo Therapeutics: Contrarian 'Buy' Ahead Of Abdakibart's Phase 3

Seeking Alpha · 25 Oct 2026positive

Seeking Alpha reports that Avalo Therapeutics' positive LOTUS results support a pivotal trial of abdakibart, with monthly dosing cited as a potential differentiator in HS. It also says the company's balance sheet can cover upcoming milestones, while AVTX-010 remains years from becoming a meaningful value driver.

Why it matters — The item highlights abdakibart's progress toward a pivotal trial and notes the longer timeline for AVTX-010.

This Avalo Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Benzinga · 23 Oct 2026negative

Benzinga's headline says an analyst covering Avalo Therapeutics is no longer bullish, as part of a roundup of five downgrades for Friday. The excerpt provides no further details about the AVTX rating change.

Why it matters — AVTX watchers may note the reported shift in an analyst's outlook, though the excerpt does not identify the analyst or specify the rating.

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 29 Sept 2026neutral

Avalo Therapeutics announced that its Compensation Committee approved grants of nonstatutory stock options to purchase an aggregate of 101,600 shares of common stock to three new employees. The inducement equity awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) as inducements material to the employees entering employment with the company.

Why it matters — The inducement grants signal onboarding of new staff and represent incremental share-based compensation for Avalo, an item of interest to shareholders tracking dilution and hiring activity.

Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress

GlobeNewsWire · 23 Sept 2026neutral

Avalo Therapeutics announced it will deliver a late-breaker oral presentation and a poster at the EADV Congress 2026, held in Vienna, Austria from September 30 to October 3, 2026. The company develops therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases.

Why it matters — AVTX watchers would care because the company's clinical program is receiving visibility through presentations at a major international dermatology conference.

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 4 Sept 2026neutral

Avalo Therapeutics announced that its Compensation Committee approved inducent equity awards, consisting of nonstatutory stock options to purchase an aggregate of 78,000 shares of common stock, granted to six new employees. The grants were made as inducements material to the employees joining the company, in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — AVTX watchers would care because the inducement equity grants signal the company's hiring and talent-acquisition activity, a routine corporate action that could result in modest share dilution.

FAQ

Frequently asked questions about AVTX stock

What is the AVTX stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Avalo Therapeutics, Inc. have a median 12-month price target of $39, with estimates ranging from $10 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AVTX stock a buy right now?

Of the 14 analysts covering Avalo Therapeutics, Inc., 12 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Avalo Therapeutics, Inc. 27 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AVTX?

As at 31 Oct 2026, Avalo Therapeutics, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (65 of 100).

Will AVTX stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +437.0% from the last close, and Ticker Nerd's factor model ranks Avalo Therapeutics, Inc. 27 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AVTX stock forecast for 2030?

No analyst covering Avalo Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AVTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $60 over the next 12 months.

How has AVTX stock performed over the past year?

Avalo Therapeutics, Inc. returned -60.2% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Avalo Therapeutics, Inc. do?

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for immune-mediated inflammatory diseases.

What is the latest news on AVTX?

The most recent item we track (Seeking Alpha, 25 Oct 2026): "Avalo Therapeutics: Contrarian 'Buy' Ahead Of Abdakibart's Phase 3". Seeking Alpha reports that Avalo Therapeutics' positive LOTUS results support a pivotal trial of abdakibart, with monthly dosing cited as a potential differentiator in HS. It also says the company's balance sheet can cover upcoming milestones, while AVTX-010 remains years from becoming a meaningful value driver.

Company

About Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for immune-mediated inflammatory diseases. The company’s current work centers on IL-1β-based treatments, with Abdakibart (AVTX-009) as its lead asset, an anti-IL-1β monoclonal antibody designed to address inflammatory conditions. Avalo Therapeutics also maintains a pipeline that includes additional immune-focused programs, reflecting its emphasis on targeting dysregulated inflammation through biologic therapies. Based in Wayne, Pennsylvania, and incorporated in 2011, the company operates within the immunology and inflammation space, where its products are aimed at diseases with significant unmet medical need.

CEO Dr. Garry A. Neil M.D. · 33 employees · United States · https://www.avalotx.com